These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 34588156)

  • 21. An Unusual Presentation of Erythema Multiforme Following the Administration of Pfizer-BioNTech COVID-19 mRNA Vaccine in a Pediatric Patient.
    Alghamdi Y; Abdulghani F; Huwait HF; Abdulghani M; Samarkandy SJ
    Cureus; 2024 Apr; 16(4):e58450. PubMed ID: 38765345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pityriasis lichenoides chronica after BNT162b2 Pfizer-BioNTech vaccine: A novel cutaneous reaction after SARS-CoV-2 vaccine.
    Drago F; Ciccarese G; Guadagno A; Parodi A
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e979-e981. PubMed ID: 35841285
    [No Abstract]   [Full Text] [Related]  

  • 23. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients.
    Miele M; Busà R; Russelli G; Sorrentino MC; Di Bella M; Timoneri F; Mularoni A; Panarello G; Vitulo P; Conaldi PG; Bulati M
    Am J Transplant; 2021 Aug; 21(8):2919-2921. PubMed ID: 34058052
    [No Abstract]   [Full Text] [Related]  

  • 24. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine.
    López-Valle A; Falkenhain-López D; Arranz CR
    Int J Dermatol; 2021 Jul; 60(7):891-892. PubMed ID: 33855706
    [No Abstract]   [Full Text] [Related]  

  • 26. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
    Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
    Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
    [No Abstract]   [Full Text] [Related]  

  • 29. A case of sensory ataxic Guillain-Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer).
    Fukushima T; Tomita M; Ikeda S; Hattori N
    QJM; 2022 Jan; 115(1):25-27. PubMed ID: 34871447
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP).
    Novembre E; Tosca M; Caffarelli C; Calvani M; Cardinale F; Castagnoli R; Chiappini E; Cravidi C; Del Giudice MM; Duse M; Licari A; Manti S; Martelli A; Ricci G; Pingitore G; Marseglia GL
    Ital J Pediatr; 2022 May; 48(1):76. PubMed ID: 35578294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute-onset dacryoadenitis following immunisation with mRNA COVID-19 vaccine.
    Murphy T; Raheem Abu Shanab A; Kang K; Lyons CJ
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35256374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time and cost of administering COVID-19 mRNA vaccines in the United States.
    Yarnoff B; Bodhaine S; Cohen E; Buck PO
    Hum Vaccin Immunother; 2021 Nov; 17(11):3871-3875. PubMed ID: 34613860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonepisodic Angioedema with Eosinophilia Following Receipt of the BNT162b2 mRNA COVID-19 Vaccine.
    Koda T; Natsumoto B; Shoda H; Fujio K
    Intern Med; 2023 Oct; 62(20):3063-3067. PubMed ID: 37468248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BNT162B2 mRNA COVID-19 Vaccine in Heart and Lung Transplanted Young Adults: Is an Alternative SARS-CoV-2 Immune Response Surveillance Needed?
    Cotugno N; Pighi C; Morrocchi E; Ruggiero A; Amodio D; Medri C; Colagrossi L; Russo C; Di Cesare S; Santilli V; Manno EC; Zangari P; Giancotta C; Bernardi S; Nicolosi L; Ciofi Degli Atti M; Raponi M; Zaffina S; Alfieri S; Kirk R; Perno CF; Rossi P; Amodeo A; Palma P
    Transplantation; 2022 Feb; 106(2):e158-e160. PubMed ID: 34954734
    [No Abstract]   [Full Text] [Related]  

  • 36. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
    Abu-Raddad LJ; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Malek JA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Al-Thani MH; Al Khal A; Butt AA; Bertollini R
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34050372
    [No Abstract]   [Full Text] [Related]  

  • 37. Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report.
    Al-Rasbi S; Al-Maqbali JS; Al-Farsi R; Al Shukaili MA; Al-Riyami MH; Al Falahi Z; Al Farhan H; Al Alawi AM
    Am J Case Rep; 2022 Feb; 23():e934399. PubMed ID: 35173141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Anti-SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine.
    Carta M; Marinello I; Cappelletti A; Rodolfi A; Cerrito E; Bernasconi C; Gottardo M; Dal Lago F; Rizzetto D; Barzon E; Giavarina D
    Am J Clin Pathol; 2022 Feb; 157(2):212-218. PubMed ID: 34463321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Galvan V; Quarleri J
    Geroscience; 2022 Feb; 44(1):57-61. PubMed ID: 34935099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.